- Home
- PTRN vs TWST Comparison
PTRN vs TWST Comparison
Compare PTRN & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTRN
- TWST
- Stock Information
- Founded
- PTRN 2013
- TWST 2013
- Country
- PTRN United States
- TWST United States
- Employees
- PTRN N/A
- TWST N/A
- Industry
- PTRN Catalog/Specialty Distribution
- TWST Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTRN Consumer Discretionary
- TWST Health Care
- Exchange
- PTRN Nasdaq
- TWST Nasdaq
- Market Cap
- PTRN 2.5B
- TWST 2.1B
- IPO Year
- PTRN 2025
- TWST 2018
- Fundamental
- Price
- PTRN $16.91
- TWST $32.21
- Analyst Decision
- PTRN Strong Buy
- TWST Buy
- Analyst Count
- PTRN 10
- TWST 9
- Target Price
- PTRN $18.11
- TWST $48.56
- AVG Volume (30 Days)
- PTRN 872.5K
- TWST 1.9M
- Earning Date
- PTRN 11-05-2025
- TWST 11-14-2025
- Dividend Yield
- PTRN N/A
- TWST N/A
- EPS Growth
- PTRN N/A
- TWST N/A
- EPS
- PTRN 0.57
- TWST N/A
- Revenue
- PTRN $2,093,416,000.00
- TWST $362,273,000.00
- Revenue This Year
- PTRN $33.90
- TWST $22.10
- Revenue Next Year
- PTRN $23.45
- TWST $16.61
- P/E Ratio
- PTRN $29.67
- TWST N/A
- Revenue Growth
- PTRN 111.34
- TWST 22.72
- 52 Week Low
- PTRN $12.00
- TWST $24.07
- 52 Week High
- PTRN $18.95
- TWST $55.33
- Technical
- Relative Strength Index (RSI)
- PTRN N/A
- TWST 53.60
- Support Level
- PTRN N/A
- TWST $30.36
- Resistance Level
- PTRN N/A
- TWST $35.13
- Average True Range (ATR)
- PTRN 0.00
- TWST 2.39
- MACD
- PTRN 0.00
- TWST 0.11
- Stochastic Oscillator
- PTRN 0.00
- TWST 58.35
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.